Mood and Anxiety DPU, Neurosciences CEDD, GlaxoSmithKline Medicines Research Centre, Verona, Italy.
Neuropharmacology. 2011 Feb-Mar;60(2-3):328-35. doi: 10.1016/j.neuropharm.2010.09.016. Epub 2010 Sep 22.
Selective NPY-Y5 antagonists are known to reduce NPY-evoked increase of food intake under free feeding conditions and drug-reinforced operant responding in rodents suggesting that NPY-Y5 receptors can regulate reinforcers, potentially by modulating the hypothalamic-limbic reward system. However, evidence published to date has revealed a limited expression of NPY-Y5 in the limbic areas. Thus, the first aim of the present study was to investigate the distribution of NPY-Y5 receptor binding sites in rat mesocorticolimbic projection areas such as the nucleus accumbens (NAc), medial prefrontal cortex (mPFC), and lateral hypothalamus (LH). Since mesocorticolimbic release of monoamines has been typically associated to the rewarding and motivational significance of reinforcers, we then compared the ability of NPY and an NPY-Y5 selective agonist, [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]hPP, to evoke changes in extracellular monoamines from these brain regions using in vivo microdialysis techniques. Intracerebral doses of each compound were selected on the basis of those previously demonstrated to trigger food intake in a separate set of animals. We found that NPY-Y5 receptors were widely distributed in both the NAc and mPFC but not in the LH nuclei. Central administration of either NPY (4.5 nmol/rat) or the NPY-Y5 agonist (0.6 nmol/rat) induced a significant increase of dopamine (DA) output of up to 150% of basal values in the NAc. In addition, NPY induced a stepped increase of norepinephrine (NE) outflow in the NAc area. Also extracellular levels of NE levels were increased by both treatments in the mPFC (150% vs basal concentration). Hypothalamic monoamine levels were unaffected by both treatments. Extracellular serotonin (5-HT) levels were also unchanged in all regions. Given the NPY-Y5 agonist paralleled the in vivo ability of NPY to increase DA, these data suggest that the release of NPY may modulate behaviours associated to accumbal DA release such reward and reinforcement by, at least in part, acting on mesocorticolimbic NPY-Y5 receptors.
选择性 NPY-Y5 拮抗剂已知可减少自由喂养条件下 NPY 诱发的食物摄入量增加,并减少啮齿动物的药物强化操作性反应,表明 NPY-Y5 受体可以调节强化物,可能通过调节下丘脑-边缘奖励系统。然而,迄今为止发表的证据表明,NPY-Y5 在边缘区域的表达有限。因此,本研究的首要目的是研究 NPY-Y5 受体结合位点在大鼠中脑皮质边缘投射区域(如伏隔核 (NAc)、内侧前额叶皮层 (mPFC) 和外侧下丘脑 (LH))中的分布。由于中脑皮质边缘释放单胺通常与强化物的奖励和动机意义相关,因此我们比较了 NPY 和 NPY-Y5 选择性激动剂 [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]hPP 从这些脑区诱发细胞外单胺变化的能力,使用体内微透析技术。每种化合物的脑内剂量是基于先前在一组单独的动物中证明可触发食物摄入的剂量选择的。我们发现,NPY-Y5 受体广泛分布于 NAc 和 mPFC,但不在 LH 核中。中枢给予 NPY(4.5 nmol/大鼠)或 NPY-Y5 激动剂(0.6 nmol/大鼠)可使 NAc 中的多巴胺 (DA) 输出增加高达基础值的 150%。此外,NPY 诱导 NAc 区去甲肾上腺素 (NE) 外流呈阶梯式增加。此外,两种处理均增加 mPFC 中 NE 水平(与基础浓度相比增加 150%)。两种处理均不影响下丘脑单胺水平。所有区域的细胞外 5-羟色胺 (5-HT) 水平也保持不变。鉴于 NPY-Y5 激动剂与 NPY 增加 DA 的体内能力平行,这些数据表明,NPY 的释放可能通过至少部分作用于中脑皮质边缘的 NPY-Y5 受体来调节与伏隔核 DA 释放相关的行为,如奖励和强化。